How Plasma Becomes Medicine: From Donation to Life-Saving Drugs (2026)

The Journey of Your Plasma: Donation to Medicine

From the moment your plasma leaves the collection bottle at the center, it begins a 7-12 month journey to become a finished medicine. Here is what happens at each stage:

Stage 1: Collection and Freezing (Day 1)

After your plasmapheresis session, your plasma is immediately frozen to -30 degrees Celsius (-22 degrees F) within a few hours of collection. This preserves the critical proteins. Each donation yields about 690-880 mL of plasma depending on your weight.

Stage 2: Testing and Quarantine (Days 1-60)

Your frozen plasma undergoes rigorous testing for infectious diseases including HIV, Hepatitis B, Hepatitis C, and syphilis. Samples are tested using nucleic acid testing (NAT) technology that can detect viral DNA and RNA even before antibodies develop. Plasma is held in quarantine until all tests are confirmed negative.

Stage 3: Pooling (Days 30-90)

Cleared plasma from thousands of donors is pooled together in massive stainless steel tanks. A single production pool may contain plasma from 10,000 to 60,000 individual donations. Pooling ensures consistent protein concentrations and provides multiple layers of viral safety since each pool is tested again.

Stage 4: Fractionation (Days 60-180)

This is where the magic happens. The pooled plasma is separated into its individual protein components. More detail on this process is provided in the next section.

Stage 5: Purification and Viral Inactivation (Days 120-270)

Each protein fraction undergoes multiple purification steps and dedicated viral inactivation treatments (solvent-detergent treatment, pasteurization, nanofiltration) to ensure the final product is completely safe.

Stage 6: Formulation, Fill, and Finish (Days 200-330)

Purified proteins are formulated into their final drug form (liquid or freeze-dried), filled into vials or IV bags, and packaged for distribution. Each lot undergoes final quality control testing.

Stage 7: Distribution to Hospitals (Days 270-365)

Finished medicines are shipped to hospitals, pharmacies, and infusion centers worldwide. A patient with primary immunodeficiency in Tokyo may be receiving medicine made from plasma you donated in Texas nine months earlier.

Fractionation: The Core Manufacturing Process

Fractionation is the industrial process of separating plasma into its individual protein components. The method used today was developed by Dr. Edwin Cohn at Harvard during World War II and has been refined over 80 years.

How Cold Ethanol Fractionation Works

The Cohn fractionation method uses controlled additions of cold ethanol (alcohol) at precise temperatures and pH levels to cause different proteins to precipitate out of solution in sequence:

1. Fraction I: Fibrinogen and clotting proteins precipitate first at low ethanol concentrations (8%) and near-freezing temperatures
2. Fraction II+III: Immunoglobulins (antibodies) precipitate at 25% ethanol, yielding the raw material for IVIG products
3. Fraction IV: Alpha and beta globulins, including alpha-1 antitrypsin, separate at intermediate conditions
4. Fraction V: Albumin, the most abundant plasma protein, remains in solution the longest and is recovered last

Modern fractionation plants also use chromatography columns to further purify specific proteins and extract additional products that Cohn's original method could not isolate efficiently.

Scale of Manufacturing

• Pool size: 10,000-60,000 donations per production batch
• Processing time: 7-12 months from donation to finished product
• Yield per liter of plasma: Approximately 25-30 grams of total protein product
• Facility size: Modern fractionation plants cover 200,000-500,000 square feet

Life-Saving Medicines Made from Your Plasma

Your single plasma donation contributes to multiple medicines simultaneously. Here are the major products derived from donated plasma:

Immunoglobulin (IVIG/SCIG) - 50% of Market Value

Immunoglobulin is the most valuable product made from plasma. It contains concentrated antibodies pooled from thousands of donors and is used to treat:

• Primary Immunodeficiency (PI): Patients whose immune systems cannot produce adequate antibodies
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A neurological disorder
• Multifocal Motor Neuropathy
• Kawasaki Disease in children
• Guillain-Barre Syndrome

A single PI patient may require 30-50 grams of immunoglobulin every 3-4 weeks for life, consuming the immunoglobulin from approximately 130 plasma donations per year.

Clotting Factors - 15% of Market Value

Clotting factor concentrates are essential for hemophilia patients:

• Factor VIII: Treats Hemophilia A (the most common form)
• Factor IX: Treats Hemophilia B (Christmas disease)
• Von Willebrand Factor: Treats Von Willebrand disease
• Fibrinogen: Used in surgical bleeding control

While recombinant (synthetic) clotting factors now exist, many patients still rely on plasma-derived products, especially in developing countries where recombinant products are cost-prohibitive.

Albumin - 20% of Market Value

Albumin is the most abundant protein in plasma and is critical for:

• Burn treatment: Severe burn patients lose massive amounts of albumin through damaged skin
• Liver disease: Patients with cirrhosis cannot produce adequate albumin
• Surgical recovery: Used to maintain blood volume during and after major surgery
• Trauma/emergency medicine: Volume replacement in hemorrhagic shock

Alpha-1 Antitrypsin (AAT) - 10% of Market Value

AAT augmentation therapy is the only treatment for Alpha-1 Antitrypsin Deficiency, a genetic condition that causes progressive lung and liver damage. Patients require weekly IV infusions for life.

Other Specialty Products - 5% of Market Value

• Hyperimmune globulins: Rho(D) immune globulin (RhoGAM), Rabies immune globulin, Tetanus immune globulin, Hepatitis B immune globulin
• C1 Esterase Inhibitor: Treats hereditary angioedema
• Antithrombin III: Prevents blood clots in deficient patients

The $30 Billion Plasma-Derived Medicine Industry

The global market for plasma-derived therapies exceeded $30 billion in 2025 and continues growing at 6-8% annually. Here is who controls this industry:

Why the U.S. Supplies 70% of the World's Plasma

The United States is the world's largest source of collected plasma because it is one of the few countries that allows paid plasma donation. Most European and Asian countries prohibit or restrict compensation, resulting in far lower collection volumes. American donors literally sustain the global supply of plasma-derived medicines.

• U.S. plasma collections: Over 55 million liters per year
• Global demand: Growing 6-8% annually due to expanded diagnosis of immunodeficiencies
• Supply gap: Demand consistently outpaces supply, which is why centers actively recruit donors

Why Human Donors Are Irreplaceable

Despite advances in biotechnology, there is no synthetic replacement for human plasma. Here is why:

• Antibody diversity: Each donor contributes antibodies from every infection and vaccine they have encountered, creating a pool of thousands of different antibodies that no lab can replicate
• Protein complexity: Plasma contains over 700 identified proteins, many of which interact in ways that cannot be reproduced synthetically
• Recombinant limitations: While recombinant clotting factors exist for some hemophilia products, IVIG and albumin have no viable synthetic alternative
• Cost barriers: Even where recombinant options exist, plasma-derived products remain more affordable for global healthcare systems

Every time you sit in that donation chair, your plasma joins a global effort to treat patients who have no other option. The 45-90 minutes you spend donating becomes medicine that someone, somewhere in the world, depends on to survive.

Frequently Asked Questions

What medicine is made from donated plasma?

Donated plasma is used to manufacture immunoglobulin (IVIG) for immune deficiencies, clotting factors for hemophilia, albumin for burns and trauma, alpha-1 antitrypsin for lung disease, and hyperimmune globulins for rabies, tetanus, and hepatitis B.

What is plasma fractionation?

Fractionation is the industrial process of separating pooled plasma into its individual protein components using cold ethanol precipitation. Developed by Dr. Edwin Cohn during World War II, this method sequentially isolates fibrinogen, immunoglobulins, other globulins, and albumin from raw plasma.

How big is the plasma medicine industry?

The global plasma-derived therapeutics market exceeds $30 billion annually and grows at 6-8% per year. The five largest companies (CSL Behring, Takeda, Grifols, Octapharma, Kedrion) operate over 1,100 collection centers in the United States alone.

Why can't plasma medicines be made synthetically?

Human plasma contains over 700 proteins and thousands of unique antibodies from every infection and vaccination each donor has experienced. This biological diversity cannot be replicated in a laboratory. While recombinant alternatives exist for a few products like clotting factors, the majority of plasma-derived medicines, especially immunoglobulin and albumin, have no synthetic substitute.